Galera Therapeutics, Inc. (GRTX)
USD 0.02
(8.11%)
USD 0.02
(8.11%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 26.14 Million USD | -40.64% |
| 2022 | 44.03 Million USD | -47.14% |
| 2021 | 83.31 Million USD | -0.94% |
| 2020 | 84.09 Million USD | -31.84% |
| 2019 | 123.37 Million USD | 40.11% |
| 2018 | 88.05 Million USD | 366.6% |
| 2017 | 18.87 Million USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 16.38 Million USD | -16.63% |
| 2024 Q1 | 19.65 Million USD | -24.83% |
| 2023 Q4 | 26.14 Million USD | -30.81% |
| 2023 Q2 | 48.27 Million USD | -19.15% |
| 2023 Q1 | 59.71 Million USD | 35.6% |
| 2023 FY | 26.14 Million USD | -40.64% |
| 2023 Q3 | 37.77 Million USD | -21.74% |
| 2022 Q3 | 50.71 Million USD | -16.97% |
| 2022 Q1 | 71.09 Million USD | -14.66% |
| 2022 FY | 44.03 Million USD | -47.14% |
| 2022 Q4 | 44.03 Million USD | -13.17% |
| 2022 Q2 | 61.07 Million USD | -14.09% |
| 2021 Q1 | 70.48 Million USD | -16.19% |
| 2021 FY | 83.31 Million USD | -0.94% |
| 2021 Q4 | 83.31 Million USD | -15.65% |
| 2021 Q3 | 98.76 Million USD | -14.32% |
| 2021 Q2 | 115.26 Million USD | 63.53% |
| 2020 Q3 | 98.07 Million USD | -14.19% |
| 2020 Q2 | 114.29 Million USD | -12.63% |
| 2020 Q1 | 130.81 Million USD | 6.03% |
| 2020 FY | 84.09 Million USD | -31.84% |
| 2020 Q4 | 84.09 Million USD | -14.25% |
| 2019 FY | 123.37 Million USD | 40.11% |
| 2019 Q3 | 79.75 Million USD | -12.4% |
| 2019 Q2 | 91.04 Million USD | 0.0% |
| 2019 Q1 | - USD | -100.0% |
| 2019 Q4 | 123.37 Million USD | 54.69% |
| 2018 Q4 | 88.05 Million USD | 0.0% |
| 2018 FY | 88.05 Million USD | 366.6% |
| 2017 FY | 18.87 Million USD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| America Great Health | 299.12 Thousand USD | -8639.039% |
| Ampio Pharmaceuticals, Inc. | 5.73 Million USD | -355.736% |
| Aridis Pharmaceuticals, Inc. | 14.69 Million USD | -77.89% |
| Biora Therapeutics, Inc. | 31.21 Million USD | 16.255% |
| Bio-Path Holdings, Inc. | 3.22 Million USD | -711.832% |
| Better Therapeutics, Inc. | 22.94 Million USD | -13.939% |
| Calithera Biosciences, Inc. | 28.67 Million USD | 8.84% |
| Comera Life Sciences Holdings, Inc. | 3.72 Million USD | -601.374% |
| Gene Biotherapeutics, Inc. | - USD | -Infinity% |
| eFFECTOR Therapeutics, Inc. | 20.54 Million USD | -27.244% |
| Eloxx Pharmaceuticals, Inc. | 21.12 Million USD | -23.756% |
| Evelo Biosciences, Inc. | 64.44 Million USD | 59.434% |
| Evolutionary Genomics, Inc. | 2.35 Million USD | -1010.63% |
| Finch Therapeutics Group, Inc. | 70.99 Million USD | 63.18% |
| Innovation1 Biotech Inc. | 75.99 Thousand USD | -34299.221% |
| Kiromic BioPharma, Inc. | 12.16 Million USD | -114.816% |
| Molecular Templates, Inc. | 35.38 Million USD | 26.12% |
| Navidea Biopharmaceuticals, Inc. | 4.37 Million USD | -497.972% |
| NexImmune, Inc. | 8.59 Million USD | -204.179% |
| Orgenesis Inc. | 14.55 Million USD | -79.639% |
| Panbela Therapeutics, Inc. | 11.8 Million USD | -121.496% |
| Point of Care Nano-Technology, Inc. | 124.64 Thousand USD | -20872.698% |
| PaxMedica, Inc. Common Stock | 5.68 Million USD | -360.196% |
| Scopus BioPharma Inc. | 392.26 Thousand USD | -6564.117% |
| Sorrento Therapeutics, Inc. | 472.84 Million USD | 94.471% |
| Statera Biopharma, Inc. | 21.16 Million USD | -23.483% |
| TRACON Pharmaceuticals, Inc. | 10.1 Million USD | -158.694% |
| Trevena, Inc. | 40.6 Million USD | 35.621% |
| Vaxxinity, Inc. | 44.35 Million USD | 41.061% |
| Vaccinex, Inc. | 3.63 Million USD | -619.939% |
| Vicapsys Life Sciences, Inc. | 39.65 Thousand USD | -65819.407% |
| Viracta Therapeutics, Inc. | 56.69 Million USD | 53.889% |
| ZIVO Bioscience, Inc. | 555.71 Thousand USD | -4604.03% |